Physician profile
Gloria Wu
NPI 1437178803
$9,675.60
in general payments reported to CMS, 2019-2025
27 companies · $2,835 in 2025
The $2,835 reported for 2025 was more than what 91% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,199 · 2020: $430 · 2021: $647 · 2022: $1,240 · 2023: $1,722 · 2024: $1,604 · 2025: $2,835.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,112 · Travel and Lodging: $46.85 · Education: $0.94.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,112.47 |
| Travel and Lodging | $46.85 |
| Education | $0.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $1,584.33 | 2021-2025 | |
| Allergan, INC. | $735.58 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $712.98 | 2019-2025 | |
| Alcon Vision LLC | $660.69 | 2022-2025 | Tryptyr, Eysuvis, Rocklatan |
| Oyster Point Pharma, INC. | $658.48 | 2022-2024 | Tyrvaya |
| Bausch & Lomb Americas INC. | $598.17 | 2022-2025 | Vyzulta, Miebo, Xiidra |
| Amgen INC. | $573.71 | 2019-2025 | Tepezza |
| Ani Pharmaceuticals, INC. | $515.85 | 2024-2025 | Purified Cortrophin Gel, Yutiq, Iluvien |
| Horizon Therapeutics Plc | $508.11 | 2023 | Tepezza |
| Abbvie INC. | $505.49 | 2023-2025 | Lumigan, Alphagan P |
| Regeneron Healthcare Solutions, INC. | $372.96 | 2019-2025 | Eylea, Eylea Hd |
| Novartis Pharmaceuticals Corporation | $282.54 | 2019-2023 | |
| Dompe US, INC. | $276.75 | 2023-2025 | Oxervate |
| Kala Pharmaceuticals, INC. | $262.23 | 2021-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $208.09 | 2019-2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $201.83 | 2022-2023 | Percept PC Brainsense |
| Insightec,INC | $143.24 | 2025 | Exablate |
| Genentech USA, INC. | $141.79 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $125.00 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $125.00 | 2019 | |
| Alexion Pharmaceuticals, INC. | $124.99 | 2019 | |
| Astellas Pharma Global Development | $108.45 | 2024 | Izervay |
| Biogen, INC. | $90.51 | 2023 | |
| Mallinckrodt Hospital Products INC. | $68.11 | 2024 | Acthar |
| Optos, INC. | $50.39 | 2019-2021 | |
| Janssen Biotech, INC. | $22.82 | 2019 | |
| Apellis Pharmaceuticals, INC. | $17.51 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gloria Wu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.